[Long-term problems of levodopa therapy in Parkinson disease].
The dependence of motor side effects of L-DOPA therapy on clinical and pharmacodynamic parameters was investigated in 28 patients with Parkinson's disease. Duration of disease and degree of motor impairment were significantly less in a first group of 12 patients without motor side effects than in a second group of 16 patients with fluctuations of antiparkinsonian effects and dyskinesias. The two groups showed different pharmacodynamic patterns: the antiparkinsonian effect in the first group remained unchanged, with decreasing DOPA plasma concentrations (Type I), whereas in the second group a direct correlation between DOPA plasma levels and antiparkinsonian effect was observed (Type II). A possible mechanism for the different pharmacodynamic patterns and its relevance for therapy are discussed.
D000328:Adult; D000368:Aged; D002851:Chromatography, High Pressure Liquid; D004295:Dihydroxyphenylalanine / Q000097:blood; D004409:Dyskinesia, Drug-Induced / Q000209:etiology*; D006801:Humans; D007980:Levodopa / Q000009:adverse effects* / Q000097:blood / Q000627:therapeutic use; D008017:Life Expectancy; D010300:Parkinson Disease / Q000188:drug therapy* / Q000401:mortality; D013997:Time Factors
D007980:Levodopa; D004295:Dihydroxyphenylalanine
Langzeitprobleme der Laevodopa-Therapie bei der Parkinsonschen Krankheit.